Copyright
©The Author(s) 2016.
World J Gastrointest Oncol. Feb 15, 2016; 8(2): 222-230
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222
Table 1 Characteristics of 41 patients in II and III line and tumours
Number of patients | Rates | Median age (range) yr | |
Gender | |||
Male (M) | 23 | 56% | 67.5 (51-84) |
Female (F) | 18 | 44% | 64.6 (49-83) |
Primary tumour | |||
Right colon | 7 | 17% | |
Left colon | 21 | 51% | |
Rectal | 13 | 32% | |
Grade | |||
G1/G2 | 27 | 65.8% | |
G3 | 13 | 31.7% | |
NA | 1 | 2.5% | |
Metastasis | |||
Liver only | 12 | 29.3% | |
Liver plus other sites | 14 | 34.1% | |
Extra-hepatic sites | 15 | 36.6% | |
Response | |||
Responders | |||
CR | 4 | 9.8% | |
PR | 12 | 29.3% | |
SD | 8 | 19.5% | |
Non-responders | |||
PD | 17 | 41.4% | |
Line of treatment | |||
II | 33 | 8% | |
III | 8 | 2% |
Table 2 FCGR2A (rs1801274; A > G), FCGR3A (rs366991; T > G) and single nucleotide polymorphism rs61764370 of KRAS 3’ untranslated region genotypes with the correspondent aminoacid change in the 41 metastatic colorectal cancer patients included in this study
Gene | SNP | Genotype | Aminoacid change | Number of subjects (%) |
FCGR2A | rs1801274 | A/A | H131H | 14 (34.1%) |
A/G | H131R | 20 (48.8%) | ||
G/G | R131R | 7 (17.1%) | ||
FCGR3A | rs396991 | T/T | F158F | 14 (34.1%) |
T/G | F158V | 21 (51.2%) | ||
G/G | V158V | 6 (14.7%) | ||
KRAS 3’ UTR | rs61764370 | T/T | --- | 32 (78%) |
T/G | --- | 9 (22%) | ||
G/G | --- | 0 (0%) |
Table 3 Comparison of characteristics of 41 patients on the basis of antibody-dependent cell-mediated cytotoxicity activity
ADCC < 71% | n = 20 | ADCC > 71% | n = 21 | P | |
Gender | |||||
Male (M) | 11 | 55% | 12 | 57% | 0.91 |
Female (F) | 9 | 45% | 9 | 43% | |
Primary tumour | |||||
Right colon | 5 | 25% | 2 | 10% | 0.282 |
Left colon | 8 | 40% | 13 | 62% | |
Rectal | 7 | 35% | 6 | 29% | |
Grade | |||||
G1/G2 | 13 | 65% | 14 | 67% | 0.872 |
G3 | 7 | 35% | 6 | 29% | |
NA | 0 | 0% | 1 | 5% | |
Metastasis | |||||
Liver only and liver plus other sites | 12 | 60% | 14 | 67% | 0.651 |
Extra-hepatic sites | 8 | 40% | 7 | 33% | |
Response | |||||
Responders | |||||
CR | 3 | 15% | 1 | 5% | 0.362 |
PR | 4 | 20% | 8 | 38% | |
SD | 3 | 15% | 5 | 24% | |
Non-responders | |||||
PD | 10 | 50% | 7 | 33% | |
Line of treatment | |||||
II | 17 | 85% | 17 | 81% | 12 |
III | 3 | 15% | 4 | 19% | |
EGFR | |||||
Neg; 1+; 2+ | 19 | 95% | 14 | 67% | 0.0522 |
3+ | 1 | 5% | 5 | 24% | |
NA | 0 | 0% | 2 | 10% |
- Citation: Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol 2016; 8(2): 222-230
- URL: https://www.wjgnet.com/1948-5204/full/v8/i2/222.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i2.222